Showing papers in "Lung Cancer in 2003"

TL;DR: Dose escalation, in a setting with conformal RT using involved field or stereotactic RT, should be the focus of developmental therapeutic strategies with inoperable stage I NSCLC to improve local control and survival.

TL;DR: The epidemic of lung cancer is not over yet, especially in southern and eastern Europe, and prevention remains the best policy, but improvement in the management of Lung cancer also remains very important.

TL;DR: In this article, a phase II clinical study was conducted to investigate the anti-tumor effects and safety of NPe6 in patients with early superficial squamous cell carcinoma of the lung.

TL;DR: A retrospective analysis of clinical course after two standard or approved chemotherapy agents in patients with advanced NSCLC who had received third- or fourth-line chemotherapy after two prior chemotherapy regimens that included platinum and docetaxel given concurrently or sequentially highlights the need for novel therapy approaches for patients with recurrent NSCLc who have failed second-line therapy.

TL;DR: There is a positive correlation between gene copy numbers and level of protein expression demonstrated by fluorescence in situ hybridization analysis and immunochemistry for EGFR and HER2, and the treatment status and therapeutic limitation with trastuzumab in lung cancer compared to breast cancer is discussed.

TL;DR: It is shown that higher levels of free circulating DNA can be detected in patients with lung cancer compared with disease-free heavy smokers by a PCR assay, and suggests a new, noninvasive approach for early detection of lung cancer.

TL;DR: Although additional study is necessary to validate these patterns as unique diagnostic tools, these "malignant" protein signatures lend themselves to identification of populations at high-risk for lung cancer and for monitoring response to lung cancer chemopreventive agents.

TL;DR: GC may offer acceptable option to patients with advanced NSCLC, especially those who are unable to receive cisplatin, and are comparable in efficacy and toxicity.

TL;DR: The results suggest that the expression and processing of each hnRNP protein in lung cancer is independently regulated and is not exclusively related to proliferation status.

TL;DR: Gender, extent of disease, PS, weight loss, haemoglobin, WBC count, platelet count, LDH, and NSE were all found to be independent prognostic factors for SCLC survival, however, the prognostic value of these factors depends highly on whether all or subsets of SclC patients are studied.

TL;DR: There was a statistically significant difference between tumors with pathologic T1N0M0 adenocarcinoma without vessel invasion and tumors with lymph node involvement or vessel invasion (invasive disease: ID) in each parameter.

TL;DR: Various signal transduction pathways appeared frequently to participate in NSCLC, and the level of EGFR expression appeared to correlate with those of activated ERK and Akt, suggesting some role of receptor overexpression in more potent downstream activation.

TL;DR: It is concluded that the stereotactic body frame based SRS is a safe and effective treatment modality for the local management of primary or metastatic lung tumors and the optimum total dose and fractionation schedule should be determined after the longer follow-up of these results.

TL;DR: Tumor size is a prognostic factor in pathologic stage IA NSCLC treated with adequate surgical resection and makes a case for further subdividing T1 lesions in resected NSClC.

TL;DR: A novel gene, TES101RP, expressed only in some small cell lung cancers (SCLC) and in testis, is identified, as confirmed by RT-PCR analysis, and may be effective for a quarter of Japanese lung cancer patients.

TL;DR: Transoesophageal endoscopic ultrasound guided fine needle aspiration qualifies as an accurate, safe and minimally invasive diagnostic technique for the restaging of mediastinal lymph nodes after induction therapy in NSCLC.

TL;DR: ZD 1839 may be effective in NSCLC patients with pretreated BM, with skin toxicity recorded in two patients, and large and prospective trials need to clarify the role of ZD 18 39 in the treatment of BM fromNSCLC.

TL;DR: Cryptophycin 52 failed to produce measurable responses utilizing this schedule, but in 40% of patients there was evidence of disease stabilization, and other schedules of cryptophycin52 should be considered.

TL;DR: The results of current study suggest that the expression level of caveolin-1 may be a candidate factor for predicting prognosis in patients with pulmonary squamous cell carcinoma.

TL;DR: It is hoped that as the understanding of the complex process of angiogenesis increases, so will the ability to design more effective targeted therapies as well as early enthusiasm for many of these agents.

TL;DR: Data indicates that serum assay of NSE is a useful marker also in NSCLC and a significant predictor of survival, independently of the other prognostic factors.

TL;DR: Aside classical variables such as age and performance status, high serum CYFRA 21-1 and high serum CgA level in SCLC are both prognostic determinants of prognosis, in particular in patients receiving conventional chemotherapy consisting of cisplatin and etoposide-based combinations.

TL;DR: Almost all diagnosed cases of Stage IA lung cancer as small as 10 mm in diameter have a malignant natural course, fatal if not treated, thus representing genuine cancer and most of these cases are curable by resection.

TL;DR: This study indicates that fascin immunoreactivity may identify subsets of pulmonary carcinoid patients with different metastatic potential to regional lymph nodes, and Targeting the fascin pathway could be a novel therapeutic strategy ofmonary carcinoids.

TL;DR: The evaluation of TA02 expression in lung tumorous lesions was very valuable for discriminating between primary and metastatic lung adenocarcinoma, and TA02 was superior to SpA as a discriminating marker.

TL;DR: DAPK expression is frequently down-regulated in lung cancers, although considerable heterogeneity of methylation is present, and some specific CpG dinucleotides are often methylated in expression negative lung cancers; and besides methylation and histone deacetylation, there may be other mechanisms for down-regulation of D APK expression.

TL;DR: It is suggested that NQO1 plays a role in the development of cigarette smoking-associated lung adenocarcinoma, and GSTP1 polymorphism was associated with the risk of squamous cell lung carcinoma in Taiwan.

TL;DR: COX-2 inhibitor, either in combination therapy with other agents, or for chemoprevention, may be effective via suppression of angiogenesis in this fatal disease.